- Single-gene mutational analysis
- Quantitative PCR
- Receptor clonality testing
Now available! Flow MRD for Myeloma, an ultrasensitive test for assessing measurable residual disease (MRD) in patients with myeloma
Flow MRD for Myeloma is raising the standard for patient care:
- Multiparameter flow cytometry, validated for monitoring minimal residual disease (MRD) in peripheral blood of patients with myeloma
- Assay sensitivity = 5 x 10-6 with only a single tube of blood
- No baseline sample required—initiate testing at any time
- Rapid 3-5 day turnaround time with enhanced, integrated reporting
Flow MRD for Myeloma by Quest Diagnostics merges elite performance with value and access, making it a great option for value-based care. This new offering complements Quest’s comprehensive portfolio of hematopathology and advanced molecular oncology testing and services.
Comprehensive hematology and hematopathology solutions across the spectrum of cancer care and management
With more than 3 decades of insights and innovations in blood cancer diagnostics, we can help support your patients through every stage of their cancer journey. We offer both routine and specialized hematopathology testing services, including
- Comprehensive diagnostic services for blood and bone marrow biopsies with trending reports
- Molecular assays, many of which were developed by our team at Quest Diagnostics Nichols Institute
- Cytogenetics, including DNA microarrays
- Flow cytometry, including specialty panels and paroxysmal nocturnal hemoglobinuria (PNH) testing
- Reference menus for fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and special stains
A single sample is all we need to work your patient’s case, from start to finish
We offer algorithms for the diagnostic workup of hematologic neoplasms and benign hematological disorders, including acute and chronic leukemias, lymphomas, myeloproliferative neoplasms, myelodysplastic syndromes, plasma cell neoplasms, coagulopathies, and hemoglobinopathies.
Our testing portfolio is based on clinically relevant and medically accepted guidelines, including NCCN®, WHO, ACMG, AMP, and IMWG, among others.
We offer cytogenetics, DNA/RNA, ISH, FISH, FLOW, IHC, and morphology
- Disease-specific panels
– MPN Core Diagnostic Panel
– LeukoVantage®
– AML Rapid Mutation Panel
The pathology and the testing that provides you with the most comprehensive insights
- Bleeding profiles and screening tests
- Von Willebrand disease
- Factor assays and inhibitors
- Anticoagulant therapy
- HIT, TTP, and platelet studies
- Fibrinolysis and markers of thrombin generation
- Thrombotic risk markers and profiles—inherited
- Antiphospholipid antibody and lupus anticoagulant
- Women’s health
Medical experts and pathologists
Our experts collaborate at every step to uncover answers for every case.
Get in touch
Hereditary cancer links
Hereditary Cancer
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.